Researcher

PD Dr. Yvonne Genzel
PD Dr. Yvonne Genzel
Phone: +49 391 6110 257
Room: N0.18
Juliana Coronel, D.Sc.
Phone: +49 391 6110 331
Room: N0.06
Links: Linkedin

Additional Information

External Collaborations:

University of Applied Sciences Emden Leer, Germany (Prof. K. Scharfenberg)

IBET, Portugal (Dr. A. Roldao)

Otto von Guericke University Magdeburg (Prof. D. Thévenin)

IDT Biologika GmbH, Dessau-Roßlau, Germany (Dr.-Ing. B. Hundt)

ProBioGen AG, Germany (Dr. V. Sandig)

Kühner AG, Switzerland (Dr. T. Anderlei)

East China University of Science and Technology (Dr. X. Liu)

Esco Aster PTE LTD (AS Yip)

CO-HEP Copenhagen University Hospital (Prof. J. Gottwein)

German Primate Center Göttingen (Prof. S. Pöhlmann)

COPPE - Universidade Federal do Rio de Janeiro (Prof. L. Castilho)

Glysantis, NRC (Dr. R. Goshal, Dr. A. Manceur)

Bielefeld University (Prof. T. Noll)

Internal Collaborations:

M. Wasik, BPE, Molecular Biology, MPI Magdeburg

J. Ramos, BPE, Mathematical Modeling, MPI Magdeburg

Scouting for new vaccine production options

Header image 1541500313

Scouting for new vaccine production options

Motivation

Processes for recombinant protein production (i.e. monoclonal antibodies) are giving the lead regarding cell line optimization, medium design, and process intensification using fed-batch or perfusion cultures. Viral vaccine industry, however, is slow in implementation of similar technologies. Therefore, our group is scouting on new vaccine production options not only for “established” vaccines but also for new vaccines for emerging diseases or for therapeutic approaches. With the aim to modernize vaccine manufacturing a knowledge base is build-up for processes using suspension and adherent cells. For this, a wide range of cultivation vessels and process strategies, i.e. fed-batch, perfusion and continuous systems, are evaluated for production of a selected set of viruses including influenza A virus, MVA virus, and flaviviruses.

Fig.1 Overview on current perfusion and continuous process strategies evaluated in the USP team. STR: stirred tank bioreactor, OSB: orbital shaken bioreactor, ATF: alternating tangential flow filtration, TFF: tangential flow filtration, IS: inclined settler, AF: acoustic filter, PBBR: packed bed bioreactor, PFBR: plug flow bioreactor. The PBBR can be operated as a perfusion as well as a continuous process. Zoom Image
Fig.1 Overview on current perfusion and continuous process strategies evaluated in the USP team. STR: stirred tank bioreactor, OSB: orbital shaken bioreactor, ATF: alternating tangential flow filtration, TFF: tangential flow filtration, IS: inclined settler, AF: acoustic filter, PBBR: packed bed bioreactor, PFBR: plug flow bioreactor. The PBBR can be operated as a perfusion as well as a continuous process.
[less]

Aim of the project

For this concept, small scale experiments using cell culture flasks up to 10 L benchtop bioreactors are evaluated for suspension cells or packed bed reactors for adherent cells using either fed-batch, perfusion or continuous operation modes. Process characterization involves the use of conventional and state-of-the art sensors for on- and off-line monitoring and the analysis of cell growth, cell metabolism, and virus replication (virus titration, flow cytometry for infection status, defective particles). Our final aim is to establish a knowledge base for intensified viral vaccine and vector production.

Towards higher cell densities...

To accomplish this strategy, many different parameters have to be analyzed experimentally and integrated into mathematical models (pH, pO2, on-line capacitance, glucose, lactate & ammonium concentration, cell growth rate, virus titer, ...). Furthermore, advanced analytical methods such as flow cytometry to characterize the properties of cell populations, or HPLC methods to determine the concentration of intracellular metabolites and specific enzyme activities during cell growth and virus replication are being used.

Variations of cell culture medium (serum-free, chemically defined), bioreactors (disposable, stirred versus orbital shaken (OSB)), viruses (influenza A and B, flaviviruses, MVA) and host cells (Vero, AGE1.CR, etc.) are evaluated in-depth for the characterization of different process conditions. Cultivation of suspension cells with perfusion results in cell concentrations of more than 8 x 107 cells/mL. We currently focus on disposable hollow fiber technology (HFBR, ATF, TFF) as well as inclined settlers or acoustic filter systems for perfusion cultures aiming not only for high cell-specific virus yields but also for smooth integration of subsequent downstream processing steps.

Towards continuous virus production...

Infecting constantly new cells that are added to the process and constantly removing virus that is produced by the cells could lead to continuous virus manufacturing processes. Two-stage stirred tank bioreactors, both running in continuous mode with a cell reactor feeding the virus vessel is one option. Alternatively, a tubular plug flow reactor (PFBR) with an infection of cells at the beginning of the tube that then flow through the tube with a given residence time could be used. Evaluating and optimizing both systems for various virus-host cell systems will complete our knowledge base and also help to better understand the generation of defective interfering particles in these systems.

Fig. 2 Hollow fiber based perfusion with an orbital shaken bioreactor (OSB) Zoom Image
Fig. 2 Hollow fiber based perfusion with an orbital shaken bioreactor (OSB)

Outlook

Fine tuning of these systems can be done with additional knowledge on intracellular metabolites, optimization of medium composition (serum-free, protein-free, chemically defined, virus booster), virus seed generation and virus-host cell interaction (reverse genetics), virus replication dynamics or cellular physiology (flow cytometry).

References

Nikolay, A.; Léon, A.; Schwamborn, K.; Genzel, Y.; Reichl, U.: Process intensification of EB66 ® cell cultivations leads to high-yield yellow fever and Zika virus production. Applied Microbiology and Biotechnology 102 (20), pp. 8725 - 8737 (2018)
Vazquez-Ramirez, D.; Genzel, Y.; Jordan, I.; Sandig, V.; Reichl, U.: High-cell-density cultivations to increase MVA virus production. Vaccine 36 (22), pp. 3124 - 3133 (2018)
Tapia, F.; Jordan, I.; Genzel, Y.; Reichl, U.: Efficient and stable production of Modified Vaccinia Ankara virus in two-stage semi-continuous and in continuous stirred tank cultivation systems. PLoS One 12 (8), e0182553 (2017)
Tapia, F.; Vogel, T.; Genzel, Y.; Behrendt, I.; Hirschel, M.; Gangemi, J. D.; Reichl, U.: Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor. Vaccine 32 (8), pp. 1003 - 1011 (2014)
 
loading content
Go to Editor View